To investigate the changes in the gut microbiota in the course of anti-PD-1 therapy in NPC patients, we performed shotgun metagenomics sequencing on fecal material collected in 50 of the patients at baseline and at several time points along the course of anti-PD-1 treatment (Supplementary Figure S2). This evidence concerns the gene PDCD1 and nasopharyngeal carcinoma.